The trial results are among the pharmaceutical industry's most critical and closely watched of the year, as they bring Eli Lilly's drug one step closer to becoming a new, needle-free alternative ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 9 trades. If we consider the specifics of ...

Berenberg Bank analyst Kerry Holford maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) on March 21 and set a price target of $970.00. The company’s shares closed last Friday at ...

Eli Lilly (LLY) will soon be releasing trial data on its small-molecule GLP-1 weight-loss pill, Orforglipron. The drug could be pivotal for the obesity treatment market due to its accessibility.

Eli Lilly has launched Mounjaro, a first-of-its-kind drug for obesity and type 2 diabetes, in India. This medication, approved by CDSCO, helps with weight management and activates hormone receptors.

Eli Lilly and Company launched its weight loss drug Mounjaro in India on Thursday after obtaining approval from the Central Drugs Standard Control Organisation (CDSCO). This is a drug which ...

Zepbound is Eli Lilly's biggest growth driver at the moment, but it isn't the only drug pushing total sales higher for this well-established pharmaceutical giant. Its fourth-quarter revenue not ...

to Eli Lilly and Company (NYSE:LLY) (“Lilly”). The transaction was completed on March 25, 2025. With the closing, Organovo receives an upfront payment, with future milestones to be paid as ...

American Drugmaker Eli Lilly on Thursday announced the launch its blockbuster drug Mounjaro in India beating its rival Novo Nordisk. Both the companies have seen skyrocketing global demand for ...

Healthcare & Pharmaceuticalscategory· March 21, 2025 Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market Eli Lilly launched its blockbuster diabetes and ...